HealthTree Logo
search more_vert
person Sign In / Create Account
Clinical Trial: Allo vs. Auto Transplant in Multiple Myeloma
Posted: Dec 07, 2022
Clinical Trial: Allo vs. Auto Transplant in Multiple Myeloma image

Using historic data, an open myeloma clinical trial aims to determine which is better - an auto stem cell transplant or allogeneic (donor) stem cell transplant in multiple myeloma.

Patients with multiple myeloma have a potentially curative treatment option: allogeneic stem cell transplant. HCT. However, the significant risk of death associated with this procedure have historically limited its use. So, autologous stem cell transplant has stayed as the standard of care for myeloma patients who are healthy enough to undergo high-dose conditioning chemotherapy. 

With the development of new therapies over the last 15 years, myeloma survival has improved significantly. Patients with myeloma who are treated today have a median life expectancy of more than six years, with some patients living more than 20 years. So, even though allo transplant has the potential to cure multiple myeloma, standard-risk myeloma patients have excellent prognoses in the era of novel therapies. Thus, decreasing the overall benefit of allo transplant.

However, the prognosis is not uniform and varies significantly, and outcomes for high-risk myeloma patients remain poor despite the best available standard therapies, with preliminary data suggesting that allo transplant should be investigated in this group of patients.

Learn more about allogeneic transplant in this HealthTree University class.

About the Study

The observational study will evaluate patients who have received allo stem cell transplant and compare their results with patients who received an autologous stem cell transplant between 1020 and 2016, matching the groups according to age and disease risk. 

Researchers will compare the following outcomes of allo transplant patients vs auto transplant patients, matching them by age and disease risk:

  • Five-year survival
  • Progression-free survival
  • Myeloma recurrence or progression, as defined by the International Myeloma Working Group (IMWG) guidelines
  • Transplant-related mortality
  • Incidence of acute/chronic Graft Versus Host Disease (GVHD)

Patients can join the study if they are: 

  • Medicare beneficiaries
  • Patients that have stage II or III multiple myeloma and/or primary plasma cell leukemia
  • Patients that are eligible to receive an allogeneic transplant from any suitable allogeneic donor (including umbilical cord blood)
  • Patients that will receive allogeneic transplant at a US transplant center

For more information about the inclusion/exclusion criteria, click here.

The study is open at the Center for International Blood and Marrow Transplant Research in Minneapolis, Minnesota.


If you need assistance finding or joining clinical trials, please contact our Patient Navigator support team at 1-800-709-1113 or at

Did you know you can find clinical trials in HealthTree Curehub?

All you have to do is create your free account at, complete your profile and find treatment options (including clinical trials) that meet your specific needs.


The author Arturo Hurtado

about the author
Arturo Hurtado

Arturo Hurtado is an International Medical Graduate who Joined HealthTree in 2020 as part of The Patient Experience team. He helps patients understand their disease panorama and navigate their myeloma through the tools and resources that HealthTree provides. He is an enthusiastic photographer, tech nerd, and aspiring food explorer who loves to travel and find new exciting experiences.

Get the latest thought leadership on Multiple Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Multiple Myeloma Newsletter" for Multiple Myeloma news, life with Multiple Myeloma stories, Multiple Myeloma clinical trials, Multiple Myeloma 101 articles and events with Multiple Myeloma experts.

Thanks to our HealthTree Community for Multiple Myeloma Sponsors:

Johnson and Johnson
Bristol Myers Squibb

Follow Us

facebook twitter